Galmed Pharmaceuticals Calls Special Meeting to Vote on Reverse Stock Split to Address Nasdaq Delisting Threat
GLMD sits 17% above its 52-week low of $0.59.
Summary
Galmed Pharmaceuticals announced a Special General Meeting of Shareholders to vote on a reverse stock split, a strategic move to address its non-compliance with Nasdaq's minimum bid price requirement and avoid delisting.
Key Events · Corporate Governance and Compliance · GLMD
-
Special Shareholder Meeting Called
Galmed Pharmaceuticals will hold a Special General Meeting on March 4, 2026, for shareholders to vote on a reverse stock split proposal.
-
Reverse Stock Split Proposed
The company proposes a framework for a reverse stock split with a ratio between 1:2 and 1:250, to be implemented at the board's discretion over 18 months.
-
Addresses Nasdaq Non-Compliance
This action directly responds to the Nasdaq non-compliance notice received on January 29, 2026, regarding the minimum bid price requirement, aiming to prevent delisting.
-
Flexibility for Multiple Splits
The framework allows for multiple reverse splits within the 18-month period, reflecting a recent Nasdaq rule amendment and indicating the company's proactive approach to long-term compliance.
Analysis · GLMD · Life Sciences
Galmed Pharmaceuticals is seeking shareholder approval for a reverse stock split, a critical measure to regain compliance with Nasdaq's minimum bid price requirement. This follows the company's disclosure on January 30, 2026, of receiving a non-compliance letter from Nasdaq. The proposed framework grants the board broad discretion to implement a reverse split at a ratio between 1:2 and 1:250, potentially in multiple increments over 18 months. This flexibility, particularly the allowance for multiple splits, suggests the company anticipates ongoing challenges in maintaining its share price above the $1.00 threshold. While necessary to avoid delisting, reverse splits are generally viewed negatively by the market as they often precede further share price declines and can make the stock less attractive to investors.
At the time of this filing, GLMD was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $0.59 to $3.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.